B of A Securities Maintains Buy on Travere Therapeutics, Lowers Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Greg Harrison maintains a Buy rating on Travere Therapeutics (NASDAQ:TVTX) but lowers the price target from $41 to $27.
September 22, 2023 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities maintains a Buy rating on Travere Therapeutics but lowers the price target from $41 to $27.
The news is directly about Travere Therapeutics. The lowered price target might indicate a potential downside risk, but the maintained Buy rating suggests that the analyst still sees potential upside. This could lead to mixed market reactions, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100